Skip to main content
. 2021 Dec 25;11(1):102. doi: 10.3390/jcm11010102

Table 1.

Literature overview of hearing impairment in beta-thalassemia.

Author and Year # Age Phenotype ICT HL SNHL CHL MHL Method HL Definition
De Virgiliis et al., 1979 [18] 75 ped. TDT DFO 73.3% 57.3% 16% n.r. PTA >20 dB in any frequency
Marsh et al., 1981 [46] 1 adult NTDT DFO 0 0 0 0 clinical interview Not Applicable
Orton et al., 1985 [47] 2 n.r. TDT DFO 100% 100% 0 0 n.r. n.r.
Barrat et al., 1987 [19] 25 mixed TDT DFO 36% 36% 0 0 PTA >20 dB in any frequency
Albera et al., 1988 [20] 153 ped. TDT DFO 71% 71% 15% n.r. PTA >20 dB in any frequency
Masala et al., 1988 [16] 100 mixed TDT DFO 24% 12% 12% n.r. PTA >10 dB in any frequency
Cohen et al., 1990 [21] 27 mixed TDT DFO 0 0 0 0 PTA >20 dB in any frequency
Porter et al., 1989 [4] *^ 30 mixed TDT DFO 23.3% 23.3% 6.7% n.r. PTA >20 dB in any frequency
Porter et al., 1989 [4] *^ 17 mixed NTDT DFO, none 23.5% 11.8% 17.6% n.r. PTA >20 dB in any frequency
Wonke et al., 1989 [34] 50 mixed TDT DFO, Ca-DTPA 26% 26% n.r. n.r. PTA >30 dB in any frequency
Triantafyllou et al., 1990 [48] 120 mixed TDT DFO 36.6% 10% 15% 12.2% n.r. n.r.
Argiolu et al., 1991 [12] 309 ped. TDT DFO 15.5% 15.5% n.r. n.r. PTA >20 dB in any frequency above 2000 Hz
Cuda et al., 1991 [35] 50 mixed TDT DFO 26% n.r. n.r. n.r. PTA >30 dB in any frequency or >25 dB in at least 2 frequencies
Sheikha et al., 1992 [39] 3 mixed NTDT n.r. 100% 66.6% 33.3% 0 n.r. n.r.
Wong et al., 1993 [49] 34 mixed TDT DFO 11.8% n.r. n.r. n.r. BAEP n.r.
Onerci et al., 1994 [22] * 27 mixed TDT DFO 92.6% 14.8% 63% 14.8% PTA >20 dB in any frequency
Onerci et al., 1994 [22] * 7 mixed NTDT none 71.4% 0 57.1% 14.2% PTA >20 dB in any frequency
Sacco et al., 1994 [36] 36 mixed TDT DFO 19.4 19.4% n.r. n.r. PTA >30 dB in any frequency
Kontzoglou et al., 1996 [23] 88 mixed TDT DFO 27.3% 27.3% 0 0 PTA >20 dB in any frequency
Levine et al., 1997 [50] 2 adult TDT DFO 50% 50% 0 0 n.r. n.r.
Meara et al., 1998 [41] 1 adult NTDT n.r. 100% 0 100% 0 n.r. n.r.
Ambrosetti et al., 2000 [29] 57 adult TDT DFO 33.3% 26.3% 7% 0 PTA >25 dB in any frequency
Passat et al., 2001 [37] 65 ped. TDT nr 29.2% 27.7% 1.5% 0 BAEP >30 dB
Karimi et al., 2002 [24] 128 n.r. TDT DFO 56% 11.7 n.r. n.r. PTA >20 dB in any frequency
Chen et al., 2005 [30] 25 mixed TDT DFO 20% 20% n.r. n.r. PTA >25 dB in any frequency
Sonbolestan et al., 2005 [14] 160 n.r. TDT DFO 48.7% n.r. n.r. n.r. PTA >25 dB in any frequency or >10 dB in two sequential frequencies
Berjis et al., 2007 [15] 160 mixed TDT DFO 50% 50% n.r. n.r. PTA >20 dB in two consecutive frequencies, or > 40 dB in one frequency
Budak et al., 2008 [31] 9 adult TDT DFO 16.6% n.r. 5.5% 11.1% PTA >25 dB in any frequency
Delehaye et al., 2008 [25] 60 mixed TDT DFO 50% 50% 0 0 PTA, DPOAE >20 dB at PTAv or increase of at least 20 dB in any frequency at follow up
Shamsian et al., 2008 [17] 67 mixed TDT DFO 7.4% 7.4% 0 0 PTA >15 dB in any frequency
Thio et al., 2008 [42] 1 ped. TDT DFO 100% 0 100% 0 n.r. n.r.
Faramarzi et al., 2010 [13] 293 mixed TDT DFO 3.5% 3.5% 0 0 PTA >20 dB in any frequency
Vir et al., 2010 [51] 26 mixed TDT DFO, DFP n.r. n.r. n.r. n.r. PTA >= 26 dB in any frequency
Chao et al., 2013 [26] 37 mixed TDT DFO, DFP 35.1% n.r. n.r. n.r. PTA >20 dB in any frequency
Uygun et al., 2013 [52] 169 mixed TDT mixed 14% n.r. n.r. n.r. n.r. n.r.
Pereira da Silva et al., 2015 [53] 2 ped. mixed none 100% 0 100% 0 PTA n.r.
Osma et al., 2015 [27] 159 mixed mixed mixed 39% 39% n.r. n.r. PTA >20 dB in any frequency
Bhardwaj et al., 2016 [33] 30 n.r. TDT mixed 23.3% n.r. n.r. n.r. PTA, DPOAE Average of 2, 4 and 8 kHz >25 dB
Badfar et al., 2017 [6] 1422 n.r. TDT DFO 27.3% 10.6% 14.6% 9.1% n.r. n.r.
Lanigan et al., 2017 [40] 1 ped. TDT DFX + DFO 100% 0 100% 0 PTA, OAE n.r.
Hasan et al., 2018 [54] 23 mixed TDT DFO, none 26.1% 4.3% 21,7% n.r. n.r. n.r.
Sirisena et al., 2018 [43] 1 ped. TDT DFX 100% 0 100% 0 n.r. n.r.
Alzaree et al., 2019 [28] 48 ped. TDT DFO 23/29%§ 23/29%§ 0 0 PTA, DPOAE >20 dB in any frequency
Khan et al., 2019 [55] 198 mixed TDT DFX 45.5% 45.5% n.r. n.r. PTA n.r.
Khalaf et al., 2020 [56] 100 mixed TDT nr 8% 8% n.r. n.r. n.r. n.r.
Manara et al., 2021 [32] * 51 adult TDT mixed 58.8% 46% 5.9% 7.8% PTA >25 dB in any frequency
Manara et al., 2021 [32] * 20 adult NTDT mixed, none 35% 25% 5% 5% PTA >25 dB in any frequency

Abbreviations: TDT: Transfusion dependent Thalassemia; NTDT: Non Transfusion dependent Thalassemia; HL: hearing loss; SNHL: Sensorineural Hearing Loss; CHL: Conductive Hearing Loss; MHL: Mixed hearing Loss; PTA: pure-tone audiometry; PTAv: pure-tone average; ICT: iron chelation therapy; DFO: deferoxamine; DFX: deferasirox; DFP: deferiprone; Ca-DTPA: calcium-diethylene triamine penta-acetic acid; BAEP: Brainstem Auditory Evoked Potentials; DPOAE: Distortion Product Otoacustic Emissions; OAE: Otoacustic Emissions. * Disaggregate data according to beta-thalassemia phenotype are presented for Porter, Onerci, and Manara. ^ one patient on deferoxamine with conductive hearing loss due to otosclerosis is mentioned, without reporting whether TDT or NTDT. This patient was not counted in the prevalence rate. § data refer to right and left ear; data on patients were not available.